Harrow announced an early completed transfer of the new drug application for Triesence, a synthetic corticosteroid for treatment of several inflammatory ophthalmic conditions, including those not responsive to topical corticosteroids.
According to a company press release, Harrow agreed to acquire the U.S. commercial rights to Triesence 40 mg/mL (triamcinolone acetonide injectable suspension) in January 2023. While the transfer was completed ahead of the previously determined date, other terms of the acquisition remain the same.
“While we continue to diligently work with our contract